Absci Q4 Earnings Call Highlights

Absci (NASDAQ: ABSI) provided a fourth-quarter and full-year 2025 business update on Monday, highlighting early progress for lead candidate ABS-201, expansion into a second indication, and continued investment in its AI-enabled drug creation platform. ABS-201 advances in the clinic with early safety and PK observations Founder and CEO Sean McClain said Absci "had a strong fourth